Recently, an interesting study entitled “MiR-21 regulates epithelial–mesenchymal transition
in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR” was published in
Digestive and Liver Disease [
[1]
]. In this study, the authors revealed that miR-21 was significantly upregulated in
the intestinal tissues from Crohn's disease (CD) patients with fibro stenosis. They
further showed that miR-21 inhibition with antagonists relieved intestinal fibrosis,
which is established by suppressing epithelial–mesenchymal transition (EMT) and regulating
extracellular matrix (ECM) remodeling. Their results established and clarified the
critical role of miR-21 in CD that may be beneficial in providing a potential therapeutic
target against CD. Although this novel discovery opens the door for new treatment
of CD, it is not known whether miR-21 inhibition represses the development of CD only
by suppressing EMT and regulating ECM remodeling, and whether inhibition of miR-21
could produce unwanted side effects.- Wang Z.
- Zhou H.
- Cheng F.
- Zhang Z.
- Long S
MiR-21 regulates epithelial-mesenchymal transition in intestinal fibrosis of Crohn's
disease by targeting PTEN/mTOR.
Dig Liver Dis. 2022; ([published online ahead of print, 2022 Apr 30]) (S1590-8658(22)00253-5)https://doi.org/10.1016/j.dld.2022.04.007
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- MiR-21 regulates epithelial-mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR.Dig Liver Dis. 2022; ([published online ahead of print, 2022 Apr 30]) (S1590-8658(22)00253-5)https://doi.org/10.1016/j.dld.2022.04.007
- Circulating exosomal miR-21 mediates HUVEC proliferation and migration through PTEN/PI3K/AKT in Crohn's disease.Ann Transl Med. 2022; 10: 258https://doi.org/10.21037/atm-22-475
- miR-21 antagonist alleviates colitis and angiogenesis via the PTEN/PI3K/AKT pathway in colitis mice induced by TNBS.Ann Transl Med. 2022; 10: 413https://doi.org/10.21037/atm-22-944
- MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin.Cardiovasc Diabetol. 2018; 17 (Published 2018 Sep 4): 123https://doi.org/10.1186/s12933-018-0767-z
- MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion.Sci Transl Med. 2012; 4: 122ra22https://doi.org/10.1126/scitranslmed.3003441
Article Info
Publication History
Published online: November 18, 2022
Accepted:
November 2,
2022
Received:
October 27,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- MiR-21 regulates epithelial–mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTORDigestive and Liver DiseaseVol. 54Issue 10
